We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
From May 2021 to May 2024
By Adria Calatayud
Redx Pharma PLC said Thursday that it has received a milestone payment from AstraZeneca PLC of $4 million on the back of progress in the development of RXC006, a preclinical drug candidate targeting fibrotic diseases.
Redx, a London-listed drug-discovery company, said the payment is part of early payments of $17 million under a licensing agreement between the two parties disclosed in August. In addition to the $17 million in payments before the start of clinical trials, Redx might receive up to a further $360 million in development and commercial-milestone payments throughout the course of the program, it said.
Redx said RXC006 is a preclinical porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis.
Shares in Redx at 0719 GMT were up 6.8% at 62.50 pence.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
June 17, 2021 03:42 ET (07:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
